Title:
NOVEL CO-CRYSTAL OF ENAVOGLIFLOZIN
Document Type and Number:
WIPO Patent Application WO/2024/072109
Kind Code:
A1
Abstract:
The present invention relates to a co-crystal of enavogliflozin. The enavogliflozin co-crystal of the present invention increased the solubility of enavogliflozin in artificial gastric fluid and artificial intestinal fluid. This improvement in the solubility of enavogliflozin can be particularly advantageous for the development of oral formulations for indications requiring high-dose administration. With the same stability as that of the existing crystalline forms of enavogliflozin, the enavogliflozin co-crystal is also very useful as a raw material for enavogliflozin pharmaceuticals. In addition, the co-crystal of the present invention maintains medicinal efficacy for a prolonged period of time compared to existing crystalline form A due to its longer half-life and higher systemic exposure (AUCinf) and thus can be usefully employed for various indications and/or in the development of formulations that require prolonged efficacy.
More Like This:
Inventors:
YOON YOUN JUNG (KR)
YOON HEE KYOON (KR)
CHOI JI SOO (KR)
JI HYE YOUNG (KR)
LIM HYUN WOO (KR)
YOON HEE KYOON (KR)
CHOI JI SOO (KR)
JI HYE YOUNG (KR)
LIM HYUN WOO (KR)
Application Number:
PCT/KR2023/015051
Publication Date:
April 04, 2024
Filing Date:
September 27, 2023
Export Citation:
Assignee:
DAEWOONG PHARMACEUTICAL CO LTD (KR)
International Classes:
C07D407/04; A61K9/14; A61K31/351; A61P3/10
Domestic Patent References:
| WO2021092341A1 | 2021-05-14 |
Foreign References:
| KR20170142904A | 2017-12-28 | |||
| KR20090015912A | 2009-02-12 | |||
| KR20140022086A | 2014-02-21 | |||
| CN112341416A | 2021-02-09 |
Attorney, Agent or Firm:
DANA PATENT LAW FIRM (KR)
Download PDF: